Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 7, 2013, Pages 826-831

  Kestens, Christine ^a   van Oijen, Martijn G H ^a,b   Mulder, Charlotte L J ^a   van Bodegraven, Ad A ^c   Dijkstra, Gerard ^d   de Jong, Dirk ^e   Ponsioen, Cyriel ^f   van Tuyl, Bas A C ^g   Siersema, Peter D ^a   Fidder, Herma H ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Adalimumab; Anti TNF ; Crohn; Infliximab; Response

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CLEMASTINE; IMMUNOMODULATING AGENT; INFLIXIMAB; PREDNISONE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ADVERSE DRUG REACTION; AGE; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INJECTION SITE REACTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NETHERLANDS; PRURITUS; RETROSPECTIVE STUDY; SMOKING; TREATMENT DURATION; TREATMENT INDICATION; URTICARIA;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84879204639     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.01.012     Document Type: Article

References (25)

1. Blonski W., Buchner A.M., Lichtenstein G.R. Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol 2011, 27:346-357.
2. Clark M., Colombel J.F., Feagan B.C., et al. American Gastroenterological Association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007, 133:312-339.
3. Etchevers M.J., Ordas I., Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. Drugs 2010, 70:109-120.
4. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
5. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
6. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
7. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
8. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
9. Rudolph S.J., Weinberg D.I., McCabe R.P. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008, 53:1033-1041.
10. Chaparro M., Panes J., Garcia V., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose escalation in patients losing response. J Clin Gastroenterol 2001, 45:113-118.
11. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
12. Sandborn W.J., Feagan B.G., Radford-Smith G., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trail. Gut 2004, 53:1485-1493.
13. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008, 1. CD006893.
14. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009, 3:47-91.
15. Panaccione R., Colombel J.F., Sandborn W.J., et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010, 31:1296-3109.
16. Arnott I.D., McNeill G., Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003, 17:1451-1457.
17. Parsi M.A., Achkar J.P., Richardson S., et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002, 123:707-713.
18. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
19. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
20. Regueiro M., Siemanowski B., Kip K.E., et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13:1093-1099.
21. Farrell R.J., Shah S.A., Lodhavia P.J., et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000, 95:3490-3497.
22. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
23. Van der Valk M.E., Van Oijen M.G., Ammerlaan M., et al. Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators. Gut 2012, 61:324-325.
24. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
25. Cohen R.D., Lewis J.R., Turner H., et al. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis 2012, 18:10-16.